Rekah Pharmaceutical Industry Second Quarter 2024 Earnings: EPS: ₪1.05 (vs ₪0.11 loss in 2Q 2023)

Simply Wall St · 08/31 06:01

Rekah Pharmaceutical Industry (TLV:REKA) Second Quarter 2024 Results

Key Financial Results

  • Revenue: ₪68.7m (down 10% from 2Q 2023).
  • Net income: ₪12.0m (up from ₪1.10m loss in 2Q 2023).
  • Profit margin: 18% (up from net loss in 2Q 2023). The move to profitability was driven by lower expenses.
  • EPS: ₪1.05 (up from ₪0.11 loss in 2Q 2023).
earnings-and-revenue-history
TASE:REKA Earnings and Revenue History August 31st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Rekah Pharmaceutical Industry shares are up 3.0% from a week ago.

Risk Analysis

We should say that we've discovered 3 warning signs for Rekah Pharmaceutical Industry (1 can't be ignored!) that you should be aware of before investing here.